Apremilast Tablet Formulation for Once-Daily Dosing and GI Tolerability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compounds that inhibit TNF-α production suffer from lack of selective action at therapeutic doses, leading to unwanted side effects, and there is a need for dosage forms of apremilast that allow once-daily dosing with reduced gastrointestinal adverse effects.
Innovation Solution
Development of oral dosage forms of the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (apremilast) with pH-dependent or pH-independent release profiles, designed for once-daily administration to enhance patient compliance and minimize adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PDE4 inhibitors are administered at therapeutic doses, then anti-inflammatory effect is achieved, but selective action is lost and unwanted side effects occur
Solution Approach 1:
The patent divides the single-dose administration into multiple sub-doses administered at different times (e.g., morning and evening doses). This segmentation allows the total therapeutic dose to be delivered while maintaining selective action at each administration point, thereby reducing unwanted side effects that occur when the full dose is administered at once.
Solution Approach 2:
The patent implements periodic administration of the PDE4 inhibitor at scheduled intervals (e.g., twice daily). This periodic dosing strategy maintains therapeutic blood levels of the drug while allowing selective action to be preserved at each dosing point, preventing the loss of selectivity and subsequent side effects associated with single high-dose administration.
2Reliability
If multiple doses per day are administered, then therapeutic efficacy is maintained, but patient compliance decreases and gastrointestinal adverse effects increase
Solution Approach 1:
The patent segments the total daily dose into multiple smaller administrations spaced throughout the day. This approach maintains therapeutic efficacy by ensuring consistent drug levels while improving patient compliance through a structured dosing schedule that is easier to follow than single high-dose regimens.
Solution Approach 2:
The patent ensures continuous therapeutic action by spacing multiple doses throughout the day, maintaining effective blood concentrations of the PDE4 inhibitor. This continuous action preserves therapeutic efficacy while the divided dosing schedule improves patient compliance compared to less manageable regimens.
3Reliability
If multiple doses per day are administered, then therapeutic efficacy is maintained, but gastrointestinal adverse effects increase
Solution Approach 1:
The patent divides the total therapeutic dose into multiple smaller sub-doses administered at different times. This segmentation reduces the gastrointestinal burden at each administration point while maintaining overall therapeutic efficacy, thereby reducing gastrointestinal adverse effects compared to single high-dose administration.
Solution Approach 2:
The patent employs periodic administration of the drug at scheduled intervals throughout the day. This periodic dosing maintains therapeutic efficacy by ensuring adequate drug levels while allowing the gastrointestinal system to recover between doses, thus reducing cumulative gastrointestinal adverse effects.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein.